A Phase 2a Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, Pharmacokinetics, and Efficacy of Deupirfenidone (LYT-100) in Patients With Breast Cancer-Related Upper Limb Secondary Lymphoedema

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 26 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deupirfenidone (Primary)
Indications Lymphoedema
Focus Adverse reactions; Pharmacokinetics; Proof of concept
Sponsors PureTech Health

Most Recent Events

26 Mar 2024 The phase of this trial has been amended to phase 2 from phase 1/2, number of treatment arms reduced to 2 from 8, no longer recruiting healthy volunteers.
11 Jan 2024 Status changed from completed to discontinued. (Primary objective/endpoint has been established, will not pursue development of the diseaseindication further )
26 Sep 2022 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight